Greg Zante, CFO of Viking Therapeutics ($VKTX), sold about 2.23 million dollars worth of shares in six open market transactions over the past year, with the latest on January 5, 2026. These sales rank 3,282nd out of 11,678 insiders, below the average of 8.59 million dollars per seller across 6.4 transactions. Zante made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 5, 2026 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 31961 | $32.30 | 215,571.0000 | 113,036,344 | 12.91% | 0.03% |
| Jan. 2, 2026 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 32049 | $0.00 | 247,532.0000 | 113,036,344 | 14.87% | 0.03% |
| Jan. 2, 2026 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 41000 | $0.00 | 215,483.0000 | 113,036,344 | 23.50% | 0.04% |
| Jan. 2, 2026 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Stock Option (Right to Buy) | 91000 | $0.00 | 91,000.0000 | 113,036,344 | 9999.99% | 0.08% |
| Jan. 5, 2026 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 1500 | $32.09 | 189,891.0000 | 113,036,344 | 0.78% | 0.00% |
| Jan. 5, 2026 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 10300 | $34.24 | 191,371.0000 | 113,036,344 | 5.11% | 0.01% |
| Jan. 5, 2026 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 13900 | $33.38 | 201,671.0000 | 113,036,344 | 6.45% | 0.01% |
| Oct. 28, 2025 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 6185 | $35.00 | 173,592.0000 | 113,036,344 | 3.44% | 0.01% |
| Oct. 27, 2025 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 11117 | $0.00 | 179,777.0000 | 113,036,344 | 6.59% | 0.01% |
| July 3, 2025 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 4266 | $27.76 | 168,660.0000 | 112,247,809 | 2.47% | 0.00% |
| July 2, 2025 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 7667 | $0.00 | 172,926.0000 | 112,247,809 | 4.64% | 0.01% |
| Jan. 3, 2025 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Stock Option (Right to Buy) | 37200 | $0.00 | 37,200.0000 | 0 | 9999.99% | 0.00% |
| Jan. 3, 2025 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 44533 | $0.00 | 193,901.0000 | 0 | 29.81% | 0.00% |
| Jan. 3, 2025 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 21667 | $0.00 | 215,568.0000 | 0 | 11.17% | 0.00% |
| Jan. 6, 2025 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 45609 | $42.69 | 169,959.0000 | 0 | 21.16% | 0.00% |
| Jan. 6, 2025 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 4700 | $43.32 | 165,259.0000 | 0 | 2.77% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Common Stock, par value $0.00001 per share | 12750 | $7.77 | 199,802.0000 | 0 | 6.82% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Common Stock, par value $0.00001 per share | 4251 | $4.68 | 204,053.0000 | 0 | 2.13% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Common Stock, par value $0.00001 per share | 26000 | $5.80 | 230,053.0000 | 0 | 12.74% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Common Stock, par value $0.00001 per share | 51000 | $8.52 | 281,053.0000 | 0 | 22.17% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 49672 | $74.56 | 231,381.0000 | 0 | 17.67% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 18620 | $75.79 | 212,761.0000 | 0 | 8.05% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 9265 | $76.94 | 203,496.0000 | 0 | 4.35% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 23082 | $77.68 | 180,414.0000 | 0 | 11.34% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Stock Option (Right to Buy) | 12750 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Stock Option (Right to Buy) | 4251 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Stock Option (Right to Buy) | 26000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Stock Option (Right to Buy) | 51000 | $0.00 | 153,000.0000 | 0 | 25.00% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 15825 | $78.69 | 164,589.0000 | 0 | 8.77% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 6050 | $79.78 | 158,539.0000 | 0 | 3.68% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 7967 | $80.65 | 150,572.0000 | 0 | 5.03% | 0.00% |
| Oct. 28, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 1206 | $81.44 | 149,366.0000 | 0 | 0.80% | 0.00% |
| July 29, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 6667 | $0.00 | 181,521.0000 | 0 | 3.81% | 0.00% |
| July 29, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 21667 | $0.00 | 203,188.0000 | 0 | 11.94% | 0.00% |
| July 30, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 12662 | $56.96 | 190,526.0000 | 0 | 6.23% | 0.00% |
| July 30, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 2974 | $57.71 | 187,552.0000 | 0 | 1.56% | 0.00% |
| July 30, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 500 | $58.71 | 187,052.0000 | 0 | 0.27% | 0.00% |
| May 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Stock Option (Right to Buy) | 30000 | $0.00 | 60,000.0000 | 0 | 33.33% | 0.00% |
| May 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Common Stock, par value $0.00001 per share | 4249 | $4.68 | 211,610.0000 | 0 | 2.05% | 0.00% |
| May 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Common Stock, par value $0.00001 per share | 30000 | $4.88 | 241,610.0000 | 0 | 14.18% | 0.00% |
| May 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 3101 | $73.49 | 238,509.0000 | 0 | 1.28% | 0.00% |
| May 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 45570 | $74.44 | 192,939.0000 | 0 | 19.11% | 0.00% |
| May 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 17238 | $75.49 | 175,701.0000 | 0 | 8.93% | 0.00% |
| May 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 847 | $76.07 | 174,854.0000 | 0 | 0.48% | 0.00% |
| May 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | M | Stock Option (Right to Buy) | 4249 | $0.00 | 4,251.0000 | 0 | 49.99% | 0.00% |
| March 27, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | F | Common Stock, par value $0.00001 per share | 16610 | $83.34 | 207,361.0000 | 0 | 7.42% | 0.00% |
| March 27, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 31667 | $0.00 | 223,971.0000 | 0 | 16.47% | 0.00% |
| March 1, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | F | Common Stock, par value $0.00001 per share | 20093 | $85.22 | 192,304.0000 | 0 | 9.46% | 0.00% |
| March 1, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 31667 | $0.00 | 212,397.0000 | 0 | 17.52% | 0.00% |
| Jan. 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 70000 | $0.00 | 240,491.0000 | 0 | 41.06% | 0.00% |
| Jan. 4, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | S | Common Stock, par value $0.00001 per share | 15000 | $17.90 | 180,730.0000 | 0 | 7.66% | 0.00% |
| Jan. 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Common Stock, par value $0.00001 per share | 28334 | $0.00 | 188,724.0000 | 0 | 17.67% | 0.00% |
| Jan. 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | F | Common Stock, par value $0.00001 per share | 18233 | $17.40 | 170,491.0000 | 0 | 9.66% | 0.00% |
| Jan. 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | A | Stock Option (Right to Buy) | 155000 | $0.00 | 155,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 4, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | F | Common Stock, par value $0.00001 per share | 13872 | $18.58 | 195,730.0000 | 0 | 6.62% | 0.00% |
| Jan. 3, 2024 | Viking Therapeutics, Inc. | $VKTX | ZANTE GREG | Chief Financial Officer | F | Common Stock, par value $0.00001 per share | 30889 | $17.40 | 209,602.0000 | 0 | 12.84% | 0.00% |